A Multi-Center Randomized Double-Blind Placebo-Controlled Sequential Panel Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2012
At a glance
- Drugs MK 0941 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 25 Jun 2012 Actual patient number is 70 as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2008 The expected completion date is now Apr 2008 (fnal data collection date for primary outcome measure), reported by ClinicalTrials.gov.